Prior inhibition of AKT phosphorylation by BX795 can define a safer strategy to prevent herpes simplex virus-1 infection of the eye.

[1]  Joshua M Ames,et al.  Drug-encapsulated carbon (DECON): A novel platform for enhanced drug delivery , 2019, Science Advances.

[2]  C. Müller-Goymann,et al.  TAT-surface modified acyclovir-loaded albumin nanoparticles as a novel ocular drug delivery system , 2019, Journal of Drug Delivery Science and Technology.

[3]  Hao Sun,et al.  Effects of Salidroside on Trabecular Meshwork Cell Extracellular Matrix Expression and Mouse Intraocular Pressure. , 2019, Investigative ophthalmology & visual science.

[4]  R. Adelung,et al.  An Intra-Vaginal Zinc Oxide Tetrapod Nanoparticles (ZOTEN) and Genital Herpesvirus Cocktail Can Provide a Novel Platform for Live Virus Vaccine , 2019, Front. Immunol..

[5]  K. Peggs,et al.  In vitro comparison of currently available and investigational antiviral agents against pathogenic human double‐stranded DNA viruses: A systematic literature review , 2019, Antiviral research.

[6]  D. Shukla,et al.  Pathogenesis of herpes simplex keratitis: The host cell response and ocular surface sequelae to infection and inflammation. , 2019, The ocular surface.

[7]  Shaohui Wang,et al.  Role of Herpes Simplex Virus Type 1 (HSV-1) Glycoprotein K (gK) Pathogenic CD8+ T Cells in Exacerbation of Eye Disease , 2018, Front. Immunol..

[8]  D. Shukla,et al.  Pathological processes activated by herpes simplex virus-1 (HSV-1) infection in the cornea , 2018, Cellular and Molecular Life Sciences.

[9]  Abraam M. Yakoub,et al.  An off-target effect of BX795 blocks herpes simplex virus type 1 infection of the eye , 2018, Science Translational Medicine.

[10]  K. Penmetcha,et al.  Targeting Herpes Simplex Virus-1 gD by a DNA Aptamer Can Be an Effective New Strategy to Curb Viral Infection , 2017, Molecular therapy. Nucleic acids.

[11]  Tejabhiram Yadavalli,et al.  Role of metal and metal oxide nanoparticles as diagnostic and therapeutic tools for highly prevalent viral infections. , 2017, Nanomedicine : nanotechnology, biology, and medicine.

[12]  M. Moschos,et al.  Herpes simplex virus keratitis: an update of the pathogenesis and current treatment with oral and topical antiviral agents , 2016, Clinical & experimental ophthalmology.

[13]  D. Shukla,et al.  Genital Herpes: Insights into Sexually Transmitted Infectious Disease , 2016, Microbial cell.

[14]  Ruchi Srivastava,et al.  Prior Corneal Scarification and Injection of Immune Serum are Not Required Before Ocular HSV-1 Infection for UV-B-Induced Virus Reactivation and Recurrent Herpetic Corneal Disease in Latently Infected Mice , 2016, Current eye research.

[15]  Yu Lin,et al.  New strategies against drug resistance to herpes simplex virus , 2016, International Journal of Oral Science.

[16]  J. Buhrman,et al.  Extended Release of an Anti–Heparan Sulfate Peptide From a Contact Lens Suppresses Corneal Herpes Simplex Virus-1 Infection , 2016, Investigative ophthalmology & visual science.

[17]  S. Kiliç,et al.  Tear Production Rate in a Mouse Model of Dry Eye According to the Phenol Red Thread and Endodontic Absorbent Paper Point Tear Tests. , 2016, Comparative medicine.

[18]  D. Shukla,et al.  Cell entry mechanisms of HSV: what we have learned in recent years. , 2015, Future virology.

[19]  K. Looker,et al.  Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012 , 2015, PloS one.

[20]  Abraam M. Yakoub,et al.  Herpes Simplex Virus-1 Fine-Tunes Host’s Autophagic Response to Infection: A Comprehensive Analysis in Productive Infection Models , 2015, PloS one.

[21]  Abraam M. Yakoub,et al.  Characterization of a Proteolytically Stable D-Peptide That Suppresses Herpes Simplex Virus 1 Infection: Implications for the Development of Entry-Based Antiviral Therapy , 2014, Journal of Virology.

[22]  G. Pasternak,et al.  Synthetic neurotensin analogues are nontoxic analgesics for the rabbit cornea. , 2014, Investigative ophthalmology & visual science.

[23]  H. Gupta,et al.  Drug delivery to the back of the eye following topical administration: an update on research and patenting activity. , 2014, Recent patents on drug delivery & formulation.

[24]  S. Garg,et al.  HIGH-SPEED OPTICAL COHERENCE TOMOGRAPHY AS A RELIABLE ADJUVANT TOOL TO GRADE OCULAR ANTERIOR CHAMBER INFLAMMATION , 2014, Retina.

[25]  G. Andrei,et al.  Herpes simplex virus drug-resistance: new mutations and insights. , 2013, Current opinion in infectious diseases.

[26]  A. Mitra,et al.  Ocular drug delivery systems: An overview. , 2013, World journal of pharmacology.

[27]  D. Shukla,et al.  Recent advances in vaccine development for herpes simplex virus types I and II , 2013, Human vaccines & immunotherapeutics.

[28]  A. Mitra,et al.  Compositions, Formulation, Pharmacology, Pharmacokinetics, and Toxicity of Topical, Periocular, and Intravitreal Ophthalmic Drugs , 2013 .

[29]  L. Morrison,et al.  Genome Sequence of Herpes Simplex Virus 1 Strain McKrae , 2012, Journal of Virology.

[30]  R. Adelung,et al.  Virostatic potential of micro-nano filopodia-like ZnO structures against herpes simplex virus-1. , 2011, Antiviral research.

[31]  Arpeet T. Shah,et al.  HSV-1 infection of human corneal epithelial cells: Receptor-mediated entry and trends of re-infection , 2010, Molecular vision.

[32]  Asim V. Farooq,et al.  Mediators and Mechanisms of Herpes Simplex Virus Entry into Ocular Cells , 2010, Current eye research.

[33]  P. Cohen,et al.  Use of the Pharmacological Inhibitor BX795 to Study the Regulation and Physiological Roles of TBK1 and IκB Kinase ϵ , 2009, Journal of Biological Chemistry.

[34]  P. Cohen,et al.  Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation. , 2009, The Journal of biological chemistry.

[35]  A. Wald,et al.  Management of herpes simplex virus type 2 infection in HIV type 1-infected persons. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  D. Koelle,et al.  Prospects for Developing an Effective Vaccine Against Ocular Herpes Simplex Virus Infection , 2005, Current eye research.

[37]  T. Rosen,et al.  Management of acyclovir-resistant herpes simplex virus. , 2003, Dermatologic clinics.

[38]  Jennifer S. Smith,et al.  Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. , 2002, The Journal of infectious diseases.

[39]  F. P. Câmara,et al.  Herpes simplex virus ophthalmic disease induced using two different methods of mice inoculation. , 2001, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[40]  Bernard Roizman,et al.  Herpes simplex virus infections , 2001, The Lancet.

[41]  P. Desai,et al.  Incorporation of the Green Fluorescent Protein into the Herpes Simplex Virus Type 1 Capsid , 1998, Journal of Virology.

[42]  Cather Jc,et al.  Herpes simplex virus type 1 infections. , 1998 .

[43]  Sociedade Brasileira de Infectologia.  The Brazilian journal of infectious diseases , 1997 .

[44]  B. Rouse,et al.  Immunopathogenesis of herpetic ocular disease , 1997, Immunologic research.

[45]  M. Lemp.  Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. , 1995, The CLAO journal : official publication of the Contact Lens Association of Ophthalmologists, Inc.

[46]  G. Elion.  Acyclovir: Discovery, mechanism of action, and selectivity , 1993, Journal of medical virology.

[47]  B. Larder,et al.  Characterization of abnormal thymidine kinases induced by drug-resistant strains of herpes simplex virus type 1. , 1983, The Journal of general virology.

[48]  S. Brown,et al.  Genetic studies with herpes simplex virus type 1. The isolation of temperature-sensitive mutants, their arrangement into complementation groups and recombination analysis leading to a linkage map. , 1973, The Journal of general virology.

[49]  A. Nesburn,et al.  EXPERIMENTAL INDUCTION OF DISCIFORM KERATITIS. , 1965, Archives of ophthalmology.